Company
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum has 20 drugs tracked on RxWires: 6 post-market, 6 in Phase 3, 3 in Phase 2/3, 2 in Phase 2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Anakinra (Kineret®) | Post-Market | Systemic Juvenile Idiopathic Arthritis (sJIA) |
| Efanesoctocog alfa | Post-Market | Hemophilia A |
| Kepivance (Palifermin) | Post-Market | Non-Hodgkin's Lymphoma |
| Pegcetacoplan | Post-Market | C3 Glomerulopathy (C3G) |
| Recombinant coagulation factor (rFVIIIFc) | Post-Market | Hemophilia A |
| Emapalumab-Lzsg 5 MG/ML [Gamifant] | Post-Market | Primary Hemophagocytic Lymphohistiocytosis |
| palifermin | Phase 3 | Cancer |
| SEL-212 low-dose | Phase 3 | Chronic Gout |
| Anakinra plus oSOC | Phase 3 | COVID-19 Infection |
| Pacritinib | Phase 3 | Primary Myelofibrosis |
| Nitisinone | Phase 3 | Hereditary Tyrosinemia, Type I |
| Emapalumab | Phase 3 | Macrophage Activation Syndrome |
| Emapalumab-Lzsg | Phase 2/3 | Hemophagocytic Lymphohistiocytoses |
| Avatrombopag 20 mg Oral Tablet | Phase 2/3 | Aplastic Anemia |
| NI-0501 | Phase 2/3 | Primary Haemophagocytic Lymphohistiocytosis |
| rhBSSL | Phase 2 | Replacement Therapy in Preterm Infants |
| Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) | Phase 2 | Autoimmune Inner Ear Disease |
| Palifermin 6 x 60 μg/kg/day | Phase 1 | Leukemia |
| Nitisinone in Arm A | Phase 1 | Drug Drug Interaction |
| Nascobal nasal spray (cyanocobalamin, USP) | Phase 1 | Focus: Bioavailability |
Latest
No recent events.
Follow Swedish Orphan Biovitrum on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.